Anti-cancer antibodies with reduced complement fixation

Details Anti-cancer antibodies with reduced complement fixation Anti-cancer antibodies with reduced complement fixation

C - Chemistry, Metallurgy

07

K

C07K 16/30 (2006.01) A61K 39/395 (2006.01) A61P 35/00 (2006.01)

Patent

CA 2553883

The invention provides modified antibodies directed against GD2 that have diminished complement fixation relative to antibody-dependent, cell-mediated cytotoxicity, which is maintained. The modified antibodies of the invention may be used in the treatment of tumors such as neuroblastoma, glioblastoma, melanoma, small-cell lung carcinoma, B-cell lymphoma, renal carcinoma, retinoblastoma, and other cancers of neuroectodermal origin.

L'invention concerne des anticorps modifiés dirigés contre GD2 qui ont une fixation complémentaire diminuée par rapport à la cytotoxicité induite par des cellules, dépendante des anticorps. Les anticorps modifiés peuvent servir dans le traitement de tumeurs telles que la neuroblastome, la glioblastome, le mélanome, le carcinome des poumons à petites cellules, le lymphome à cellules B, le carcinome rénal, le rétinoblastome, et d'autres cancer d'origine neuroectodermique.

Affiliated with

Also associated with

Rating

Anti-cancer antibodies with reduced complement fixation does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Anti-cancer antibodies with reduced complement fixation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-cancer antibodies with reduced complement fixation will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1412925